Merck and GE Healthcare have entered a collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational PET imaging agent, to support Merck’s development of MK-8931, an oral beta amyloid precursor protein inhibitor for Alzheimer’s disease (AD).   GE Healthcare will supply [18F]Flutemetamol for clinical trials and evaluate this investigational agent as a companion diagnostic tool. A joint Merck and GE Healthcare Imaging Advisory Committee will oversee the s...